Arterial Cannula Market Size & Share 2026-2035

Arterial Cannula Market Size

The global arterial cannula market was valued at USD 24.7 million in 2025 and is projected to grow from USD 26.4 million in 2026 to USD 50 million by 2035, expanding at a CAGR of 7.3%, according to the latest report published by Global Market Insights Inc.

This substantial growth is driven by increasing prevalence of cardiovascular disorders, growing, use of respiratory and cardiac support in critical care settings, advancements in cannula design and availability of reimbursements and coverage for cardiac and critical care procedures.

The market increased from USD 21.5 million in 2023 to USD 23.1 million in 2024. The rising global burden of cardiovascular diseases (CVDs) is a major driver of growth in the market. According to the World Health Organization (WHO), CVDs remain the leading cause of death worldwide, with an estimated 19.8 million deaths in 2022, accounting for nearly 32% of all global fatalities. Notably, 85% of these deaths were attributed to heart attacks and strokes, underscoring the escalating demand for advanced cardiovascular care and surgical interventions.

As the incidence of coronary artery disease, heart failure, and other cardiac conditions increases, the need for procedures such as cardiopulmonary bypass, extracorporeal membrane oxygenation (ECMO), and complex cardiac surgeries continues to grow. Arterial cannulas serve as a critical component in these procedures, enabling precise vascular access, efficient blood flow management, and improved patient outcomes. Furthermore, aging populations, sedentary lifestyles, and rising prevalence of risk factors such as obesity, diabetes, and hypertension further accelerate the demand for arterial cannulation devices. Collectively, these trends significantly strengthen the market’s growth by driving continuous adoption of advanced arterial cannulas in both surgical and critical care settings.

Additionally, the availability of favorable reimbursement policies and insurance coverage for cardiac and critical care procedures significantly drives the arterial cannula market. Many healthcare systems globally provide reimbursement for life‑saving interventions such as cardiopulmonary bypass surgeries, ECMO therapy, and other invasive cardiac procedures, reducing the financial burden on patients and hospitals. This structured coverage encourages greater adoption of advanced cardiovascular treatment protocols that rely heavily on arterial cannulas for safe and effective circulatory support.Moreover expanding government-funded health programs and private insurance coverage for critical care treatments further enhance patient access to high-cost procedures. As a result, hospitals and surgical centers are more inclined to invest in high‑quality arterial cannulation devices, strengthening market demand and supporting continuous technological advancements.
 

An arterial cannula is a specialized, flexible tube inserted into an artery to enable controlled arterial access during procedures such as cardiopulmonary bypass (CPB), ECMO, and major cardiovascular surgeries. It facilitates the delivery of oxygenated blood from extracorporeal circuits back into the patient’s arterial system. Designed to support high flow rates, arterial cannulas feature reinforced structures to ensure stability, minimize vessel trauma, and maintain reliable perfusion throughout critical procedures.

Arterial Cannula Market Trends

• Continuous technological advancements in arterial cannula design are significantly accelerating market growth. Manufacturers are increasingly developing cannulas that support minimally invasive cardiac and extracorporeal procedures by incorporating smoother atraumatic tips, smaller diameters, and greater flexibility. These improvements reduce vascular injury, simplify insertion, and enhance patient recovery.
   
• In addition, next‑generation arterial cannulas often include advanced antithrombotic or heparin-based coatings that lower the risk of clot formation, improving biocompatibility and ensuring safer long-duration procedures such as ECMO. The integration of embedded sensors to monitor parameters like flow, pressure, and oxygenation in real time is further improving procedural accuracy.
   
• The market is also benefiting from a shift toward biodegradable and eco‑friendly materials, addressing sustainability concerns while maintaining device performance.
   

Arterial Cannula Market Analysis

Based on size, the market is segmented into 14-16 Fr, 17-19 Fr, 20-22 Fr, 23-25 Fr, 26-28 Fr, 29-31 Fr, 32-34 Fr, and 35-36 Fr. The 20-22 Fr segment held significant share in the market with a revenue of USD 7 million in 2025.
 

• The 20–22 Fr arterial cannula segment holds a dominant market position primarily due to its widespread use in adult cardiac surgeries and ECMO procedures. Its size range aligns optimally with adult arterial anatomy, enabling clinicians to achieve efficient perfusion while minimizing procedural complexity. This strong clinical fit results in higher adoption rates across major cardiac centers.
   
• Additionally, the 20–22 Fr category provides a less invasive option, reducing the risk of vascular trauma, bleeding, and insertion-related complications. These safety advantages support its preference among surgeons, particularly when balancing flow performance with patient recovery outcomes. As minimally invasive approaches continue to expand, this size range remains the practical standard.
   
• Furthermore, manufacturers also prioritize innovation in this size range, integrating smoother tip designs, enhanced flexibility, and advanced coatings to improve biocompatibility and procedural safety. The concentration of design improvements around 20–22 Fr devices further strengthens their competitive positioning, making them the preferred option for hospitals seeking reliable, safe, and adaptable cannulation solutions.
   

Based on application, the arterial cannula market is segmented into cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, and other applications. Cardiopulmonary bypass surgery segment dominated the market with the largest revenue of USD 14.3 million in 2025.
 

• Cardiopulmonary bypass surgery represents the largest application area for arterial cannulas because it is essential to high‑risk cardiac procedures such as CABG, valve repair or replacement, and heart transplantation. These surgeries rely on CPB to maintain circulatory and respiratory function while the heart is temporarily stopped. The frequency of such procedures directly sustains high demand for arterial cannulation devices.
   
• The scale of CABG surgeries alone significantly contributes to this segment’s expansion. With an estimated 400,000 CABG procedures performed annually according to NIH, arterial cannulas remain indispensable in ensuring controlled blood diversion to the bypass machine. This substantial procedural volume continuously drives product utilization across surgical centers.
   
• In addition, vendors continue to enhance cannula designs to optimize performance specifically for CPB applications, including improved flow characteristics, smoother insertion profiles, and biocompatible coatings. These advancements strengthen clinical confidence and support recurring purchases, further reinforcing the segment’s strong position within the market.
   

Based on end use, the arterial cannula market is segmented into hospitals, ambulatory surgical centers, and other end users. The hospitals segment accounted for the highest market share of 72.9% in 2025.
 

• Hospitals serve as the primary setting for advanced cardiac and critical care procedures, making them major users of arterial cannulas. High‑acuity interventions such as cardiopulmonary bypass, ECMO therapy, and complex cardiac surgeries are performed in hospital operating rooms and ICUs. As these procedures continue to rise, hospitals generate the largest demand for arterial cannulation devices.
   
• The growing number of cardiac surgeries, organ transplants, and critical care treatments further expands arterial cannula utilization in hospital environments. Facilities equipped with specialized cardiac units and transplant centers routinely require reliable cannulation systems to support high-risk interventions. This consistent procedural volume contributes directly to the segment’s strong revenue contribution.
   
• Hospitals also manage broad and diverse patient flows across cardiology, intensive care, trauma, and emergency departments. These departments frequently encounter acute conditions such as cardiac arrest, vascular trauma, or respiratory failure that may require rapid arterial access or extracorporeal support. The wide patient base naturally increases procurement frequency.
   
• Manufacturers prioritize hospital-focused product innovation, offering cannulas designed for ease of insertion, better flow performance, and improved biocompatibility to enhance procedural safety. Hospitals, in turn, benefit from standardized protocols, established clinical expertise, and procurement capacity, reinforcing their position as the largest end‑user segment in the market.
   

North America Arterial Cannula Market

The North America region accounted for 42.5% of the global market in 2025. The market in North America is experiencing robust expansion, driven by the increasing prevalence of cardiovascular disorder.
 

• The growing prevalence of cardiovascular disorders across North America is a key factor supporting sustained demand for arterial cannulas. In Canada alone, heart disease remains a major health concern, ranking as the second leading cause of death and claiming over 55,000 lives annually. This high disease burden continues to push healthcare systems toward advanced cardiac interventions requiring reliable arterial access.
   
• As the region faces rising risk factors including hypertension, obesity, and diabetes the number of individuals needing interventions such as cardiopulmonary bypass, ECMO, and major cardiac surgeries continues to grow. With hospitals handling the bulk of these procedures, arterial cannulas remain essential devices, reinforcing steady revenue growth in the North American market.
   
• The growing burden of cardiovascular disease in the U.S. continues to fuel demand for arterial cannulas across surgical and critical care settings. According to the CDC, 919,032 Americans died from cardiovascular disease in 2023, representing 1 in every 3 deaths nationwide.  This high mortality rate reflects the substantial patient population requiring advanced diagnostic, interventional, and surgical cardiovascular treatment.
   
• As hospitals treat increasing numbers of patients with heart disease, coronary artery disease, and heart failure, reliance on procedures such as cardiopulmonary bypass, ECMO, and other cardiac surgeries remains high. Each of these interventions requires precise arterial access, positioning arterial cannulas as essential devices in managing acute and chronic cardiovascular conditions across major U.S. healthcare centers.
   

Europe Arterial Cannula Market

Europe market accounted for USD 7 million in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• The rising use of respiratory and cardiac support therapies across European critical care units is contributing to sustained demand for arterial cannulas. In recent years, the number of patients requiring ECMO for severe respiratory and cardiac failure has increased significantly, reaching its highest levels during the COVID‑19 period. This continued reliance on advanced life‑support systems highlights the need for dependable arterial access solutions.
   
• Across Europe, ECMO services are expanding within specialized centers as well as broader hospital networks, reflecting a growing emphasis on managing complex cardiopulmonary conditions. Countries such as the UK and Germany demonstrate varying model from centralized referral hubs to widespread availability yet both show a consistent rise in ECMO utilization for emergency and critical situations. These trends reinforce the steady consumption of arterial cannulas used in these therapies.
   

UK arterial cannula market is projected to experience steady growth between 2026 and 2035.
 

• The UK is witnessing a growing need for cardiopulmonary bypass surgeries, heart transplants, and ECMO support as cardiovascular conditions such as coronary artery disease, heart failure, and stroke continue to rise. Data from the British Heart Foundation shows that over 39,000 individuals in the UK died prematurely from heart attacks and strokes in 2022, highlighting the increasing clinical burden. This escalating prevalence is driving broader utilization of arterial cannulas across hospitals and specialized cardiac centers.
   
• Additionally, expanded government commitment to strengthening cardiac care infrastructure is fostering advancements in cardiovascular treatment technologies. Increased funding toward improving patient care pathways is enhancing research and encouraging innovation in critical devices, including arterial cannulas.
   
• Overall, the continued evolution of cardiac care, supported by rising clinical needs and sustained investment, is positioning the market for steady advancement.
   

Asia Pacific Arterial Cannula Market

The Asia Pacific region is projected to show a lucrative growth of about 8.3% during the forecast period.
 

• The rising prevalence of cardiovascular disorders across the Asia‑Pacific region is contributing to a steady expansion in the need for advanced cardiac and extracorporeal support procedures. As healthcare systems encounter increasing numbers of patients requiring interventions such as cardiopulmonary bypass, ECMO, and complex cardiac surgeries, arterial cannulas are becoming an essential component of routine and emergency cardiovascular care.
   
• Diverse patient demographics, combined with widespread risk factors such as hypertension, lifestyle changes, and rapid urbanisation, are prompting hospitals to strengthen their cardiovascular treatment capabilities. As a result, more healthcare facilities are integrating modern arterial cannulation solutions to support critical procedures, improve procedural safety, and enhance overall treatment efficiency.
   

Japan arterial cannula market is poised to witness lucrative growth between 2026 – 2035.

• Japan benefits from a highly sophisticated healthcare ecosystem, supported by advanced hospitals, research institutions, and cardiac care centers capable of performing complex procedures such as cardiopulmonary bypass, heart transplantation, and ECMO. The country’s strong clinical infrastructure enables consistent adoption of high‑precision surgical and extracorporeal technologies, including arterial cannulas used in critical circulatory support.
   
• In addition, Japan’s rapidly aging population one of the oldest in the world continues to drive demand for cardiac interventions. As a growing share of older adults require treatments for degenerative cardiovascular conditions, the need for procedures that rely on arterial cannulation becomes increasingly significant across both acute and long‑term care settings.
   
• Together, these factors position Japan as an important market for advanced arterial cannulation devices, with its mature healthcare system and demographic profile ensuring consistent demand and long‑term opportunities for innovation and product adoption.
   

Latin America Arterial Cannula Market 

Brazil is experiencing significant growth in the market
 

• The growing incidence of cardiovascular disorders in Brazil is exerting significant pressure on the country’s healthcare system, leading to a rising need for advanced cardiac and perfusion technologies. Cardiovascular diseases remain a major health challenge, accounting for a substantial proportion of national mortality and contributing to ongoing demand for life‑support and surgical interventions. This escalating burden directly supports the use of arterial cannulas in procedures such as cardiopulmonary bypass, vascular surgeries, and acute cardiac care.
   
• As hospitals expand their cardiology programs and invest in surgical and critical care capabilities, arterial cannulas play a significant role in supporting high‑acuity interventions. The continued rise in cardiovascular treatment volume positions Brazil as an important growth market for arterial cannulation devices, with sustained demand expected across public and private healthcare providers.
   

Middle East and Africa Arterial Cannula Market 

• Saudi Arabia’s ongoing transformation of its healthcare sector under the Vision 2030 initiative is accelerating the establishment of modern hospitals, specialty centers, and advanced clinical infrastructure. As these facilities expand their capabilities for high‑acuity and technically demanding procedures, the requirement for sophisticated medical devices such as arterial cannulas used in complex surgeries and critical care continues to rise.
   
• The country is also emerging as a key destination for medical tourism within the Middle East, supported by a growing reputation for high‑quality care and expanding private healthcare investment. With increasing numbers of regional and international patients seeking advanced treatment options, the demand for cardiovascular and surgical services has intensified, further boosting the use of arterial cannulation systems in clinical settings.
   

Arterial Cannula Market Share

• The top players in the market include Medtronic, LivaNova, Getinge, Andocor, and Becton, Dickinson & Company. These players collectively accounted for an estimated 45% share of the global market in 2025.
   
• Leading manufacturers in the market are increasingly focusing on advanced perfusion technologies and device optimization to enhance surgical efficiency and patient safety. Companies are integrating features such as improved flow‑dynamics engineering, reinforced low‑trauma tubing, real‑time pressure/flow monitoring, and ergonomic insertion systems. These advancements support safer cardiopulmonary bypass (CPB), ECMO, and complex cardiovascular procedures by improving cannulation accuracy, minimizing vascular injury, and ensuring stable hemodynamic performance during high‑risk surgeries.
   
• Market participants are also broadening clinical collaborations with cardiac surgery centers, ECMO programs, perfusion departments, and critical care networks. These partnerships facilitate wider deployment of next‑generation arterial cannulas, ensure seamless compatibility with oxygenators and heart–lung machines, and support training programs for perfusionists and cardiac surgeons. Such alliances are particularly influential in rapidly developing healthcare markets across Asia‑Pacific, Latin America, and the Middle East, where investments in cardiothoracic surgery and extracorporeal life support are increasing at a fast pace.
   
• As demand for complex cardiovascular interventions grows, manufacturers are strengthening compliance with evolving regulatory and quality standards governing cardiac surgery devices. Emphasis on biocompatibility, sterility, anticoagulant coatings, and performance consistency is becoming central to product development.
   
• Emerging regional suppliers are prioritizing cost‑efficient arterial cannula designs and scalable manufacturing capabilities to meet the needs of value‑driven healthcare markets. These companies focus on offering reliable yet affordable cannulation solutions, including reinforced aortic cannulas, femoral arterial cannulas, and pediatric variants tailored to diverse surgical requirements.
   

Arterial Cannula Market Companies

Few of the prominent players operating in the arterial cannula industry include:

• Andocor
• B. Braun
• Becton, Dickinson and Company
• Edward Lifesciences
• Freelife Medical
• Fresenius Medical Care
• Getinge
• LivaNova
• Medtronic
• Nipro Corporation
• Polymedicure
• Terumo Corporation
• Eurosets
   
• Eurosets

Eurosets expands its role in the market with a diverse portfolio tailored for CPB, ECLS, and minimally invasive cardiac surgery. Its devices prioritize optimized flow, structural reliability, and streamlined procedural handling, enabling high‑performance integration into extracorporeal systems and supporting advanced perfusion workflows in hospitals internationally.
 

• Andocor

Andocor enhances its standing through precision‑engineered arterial cannulation solutions developed for cardiac surgeries requiring stable, low‑trauma access. The company's focus on reinforced structures, ergonomic insertion characteristics, and dependable flow control ensures consistent performance across perfusion setups, making it a trusted supplier for cardiovascular centers worldwide.
 

• Becton, Dickinson & Company

BD supports arterial access needs through clinically reliable devices used for invasive monitoring and perioperative vascular entry. While centered on diagnostic and monitoring workflows rather than high‑flow extracorporeal circuits, BD’s arterial access solutions remain widely adopted in critical care environments, reinforcing the company's global presence in hospital‑based arterial line.
 

Arterial Cannula Industry News

• In April 2021, Nipro Medical Corporation established its Vascular Division in the U.S., expanding its presence in cardiovascular access and procedural solutions.  Although the division initially centered on vascular and imaging technologies, the move strengthened Nipro’s broader positioning in circulatory care and enhanced its credibility among cardiac surgery and interventional teams. By leveraging its expanded portfolio and commercial footprint, Nipro increased engagement with hospitals and perfusion specialists, indirectly boosting its competitiveness and visibility in adjacent markets.
   

The arterial cannula market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Size

• 14-16 Fr
• 17-19 Fr
• 20-22 Fr
• 23-25 Fr
• 26-28 Fr
• 29-31 Fr
• 32-34 Fr
• 35-36 Fr

Market, By Application

• Cardiopulmonary bypass surgery
• Extracorporeal membrane oxygenation
• Other applications                                             

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE